For monthly dosing, PCSK9 levels were reduced more in the moderate-intensity statin groups (up to 33%) than in the high-intensity statin groups (up to 16%) (eTable 5 in Supplement). Tolerability and Safety Adverse events occurred in 36% of evolocumab-treated patients, 40% of ezetimibe-...